Mollie E. Moran

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn et al. · Blood · 2004 · 403 citations · Full text

Medicine, Oncology, Pharmacology +16

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd, Thomas S. Lin, James T. Dalton et al. · Blood · 2006 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

Thomas S. Lin, Amy S. Ruppert, Amy J. Johnson et al. · Journal of Clinical Oncology · 2009 · 222 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson et al. · Blood · 2008 · 155 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

Guido Marcucci, Wendy Stock, Guowei Dai et al. · Journal of Clinical Oncology · 2005 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17